Importantly, however, JAK2 V617F allele burdens of greater than 50% in MF patients have also been associated with favorable responses to ruxolitinib (27), suggesting that MPN patients with elevated hs-CRP or PTX-3 may benefit from aggressive JAK inhibitor therapy. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.